

Supplementary Information

Copper-Catalyzed Benzylic C(sp³)-H Alkoxylation of Heterocyclic Compounds

Noriaki Takemura,^a Yoichiro Kuninobu,^{*a,b} and Motomu Kanai^{*a,b}

^a Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

^b ERATO, Japan Science and Technology Agency (JST), Kanai Life Science Catalysis Project, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

General. All reactions were carried out in a dry solvent under an argon atmosphere. Chlorobenzene, 4,7-dimethoxy-1,10-phenanthroline, *tert*-butyl peroxide, and (-)-sparteine were purchased from Sigma-Aldrich Co. and were used without further purification. CuBr and CuBr₂ were purchased from nacalai tesque and were used without further purification. 5,6-Dimethyl-1,10-phenanthroline was purchased from Tokyo Chemical Industry Co. and were used without further purification. NMR spectra were recorded on JEOL ECX500 (500 MHz for ¹H NMR and 125 MHz for ¹³C NMR), and JEOL ECS400 (400 MHz for ¹H NMR and 100 MHz for ¹³C NMR) spectrometer. Proton chemical shifts are reported relative to residual solvent peaks (CDCl₃ at δ 7.26 ppm, DMSO-*d*₆ at δ 2.50 ppm). Carbon chemical shifts are reported relative to CDCl₃ at δ 77.00 ppm or DMSO-*d*₆ at δ 39.50 ppm. IR spectra were recorded on a JASCO FT/IR-410. ESI-mass spectra were measured on a JEOL JMS-T100LC AccuTOF spectrometer (for HRMS). The enantiomeric excesses (*ee*'s) were determined by HPLC analysis conducted by JASCO HPLC systems with Daicel CHIRALPAK column.

Preparation of 1a (1d, 1e, 1f, 1g, and 1k were synthesized by the same method). To a suspension of 2-methyl-1*H*-benzo[*d*]imidazole¹ (430 mg, 3.25 mmol), 2,2-diphenyloxirane² (1.30 g, 6.62 mmol) in ethanol (3.0 mL) was added sodium acetate (270 mg, 3.29 mmol). After heating under reflux conditions for 12 h, the solvent was removed in vacuo. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄, and concentrated in vacuo to give a white solid. This residue was washed with ethyl acetate and dried in vacuo to give **1a** (755 mg, 71% yield).

Preparation of 1b (1c, 1l, 1m, and 1n were synthesized by the same method). To a solution of 2-methyl-1*H*-benzo[*d*]imidazole¹ (430 mg, 3.25 mmol) in DMF (5.0 mL) was added sodium hydride (60% in mineral oil, 143 mg, 3.58 mmol) at 0 °C and the reaction mixture was stirred at 0 °C for 1 h. Then, 2-(4-methoxyphenyl)-2-phenyloxirane² (810 mg, 3.58 mmol) was added. The reaction mixture was stirred at 60 °C for 12 h. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄, and concentrated in vacuo to give a white solid. This residue was washed with ethyl acetate/hexane and dried in vacuo to give **1b** (569 mg, 49% yield).

Preparation of 1h (1i and 1j were synthesized by the same method). A mixture of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (344 mg, 1.65 mmol), 2-amino-1,1-diphenylethanol³ (351 mg, 1.65 mmol), *N,N*-diisopropylethylamine (213 mg, 1.65 mmol), and acetonitrile (2.0 mL) was stirred at 80 °C for 12 h. Then, the solvent was removed in vacuo. After filtering over a short pad of silica gel and concentration, yellow solid was obtained and used without further purification. This intermediate was dissolved in ethanol (5.0 mL), and 10% Pd/C (50% wet type, 100 mg) was added. Then the mixture was stirred under a hydrogen atmosphere for 3 h, and the mixture was filtered through celite. Then, the solvent was removed in vacuo. A mixture of the residue, 1,1,1-trimethoxyethane (207 mg, 1.72 mmol), *p*-toluenesulfonic acid monohydrate (22.0 mg, 0.116 mmol), and toluene (5.0 mL) was stirred under an argon atmosphere at 50 °C for 3 h. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give **1h** (280 mg, 43% yield).

Preparation of 1o. A mixture of 1-fluoro-2-nitrobenzene (474 mg, 3.36 mmol), 4-amino-2-methyl-2-butanol (520 mg, 5.04 mmol), *N,N*-diisopropylethylamine (651 mg, 5.04 mmol), and acetonitrile (3.0 mL) was stirred at 80 °C for 12 h. Then, the solvent was removed in vacuo. After filtering over a short pad of silica gel and concentration, yellow solid was obtained and used without further purification. This intermediate was dissolved in ethanol (10 mL), and 10% Pd/C (50% wet type, 100 mg) was added. Then stirred under a hydrogen atmosphere at 50 °C for 3 h, and the mixture was filtered through celite. Then, the solvent was removed in vacuo. A mixture of the residue,

1,1,1-trimethoxyethane (604 mg, 5.03 mmol), *p*-toluenesulfonic acid monohydrate (64.0 mg, 0.336 mmol), and toluene (10 mL) was stirred under an argon atmosphere at 50 °C for 12 h. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (ethyl acetate/methanol = 10/1) to give **1o** (601 mg, 82% yield).

Preparation of 1p.

Boron tribromide (1.0 M dichloromethane solution, 1.01 mL, 1.01 mmol) was added drop-wise to a solution of 1-(2-methoxyphenyl)-2-methyl-1*H*-benzo[*d*]imidazole⁴ (100 mg, 0.420 mmol) in dichloromethane (3.0 mL) at 0 °C. The reaction mixture was stirred for 24 h at 25 °C. Water was added and the crude mixture was extracted with dichloromethane. The combined organic extracts were washed with water, dried over Na₂SO₄. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (ethyl acetate/methanol = 20/1) to give **1p** (77.0 mg, 82% yield).

Preparation of 1q. To a solution of 5-methyl-1*H*-tetrazole (1.00 g, 11.9 mmol), 2-methyl-2-phenyloxirane (1.92 g, 14.3 mmol) in DMF (10 mL) was added cesium carbonate (5.81 g, 17.8 mmol). The reaction mixture was stirred at 100 °C for 12 h. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give **1q** (1.51 g, 58% yield).

Preparation of 1r (1s was synthesized by the same method). To a solution of 2-methylquinazolin-4(3*H*)-one (1.00 g, 6.24 mmol), 2-methyl-2-phenyloxirane (1.01 g, 7.53 mmol) in DMF (10 mL) was added cesium carbonate (3.05 g, 9.36 mmol). The reaction mixture was stirred at 100 °C for 12 h. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give **1r** (0.930 g, 51% yield)

Preparation of 1t. To a solution of 2-methyl-1*H*-benzo[*d*]imidazole (1.00 g, 7.57 mmol) in DMF (10 mL) was added sodium hydride (60% in mineral oil, 363 mg, 9.08 mmol) at 0 °C and the reaction mixture was stirred at 0 °C for 0.5 h. Then, 1-bromo-2-propanone (1.14 g, 8.33 mmol) was added. The reaction mixture was stirred at 25 °C 2 h. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄, and concentrated in vacuo to give a white solid. This residue was washed with ethyl acetate/hexane and dried in vacuo. Pale yellow solid was obtained and used without further purification. This intermediate was dissolved in methanol (10 mL), and sodium borohydride (163 mg, 4.31 mmol) was added at 0 °C and the reaction mixture was stirred at 0 °C for 2 h. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄, and concentrated in vacuo to give a white solid. This residue was washed with ethyl acetate and dried in vacuo to give **1t** (633 mg, 49% yield).

Preparation of 1u. To a solution of 2-methyl-1*H*-benzo[*d*]imidazole (1.00 g, 7.57 mmol) and 2-bromoethanol (1.13 g, 9.04 mmol) in DMF (20 mL) was added potassium carbonate (2.10 g, 15.2 mmol). The reaction mixture was stirred at 60 °C for 8 h. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (ethyl acetate /methanol = 10/1) to give **1u** (0.643 g, 48% yield) as a white powder. The spectroscopic data were identical to the reported.⁵


Preparation of 3. To a solution of 2-methyl-1*H*-benzo[*d*]imidazole (3.00 g, 22.7 mmol) in DMF (30 mL) was added sodium hydride (60% in mineral oil, 1.09 g, 27.2 mmol) at 0 °C and the reaction mixture was stirred at 0 °C for 1 h. Then, iodomethane (3.55 g, 25.0 mmol) was added. The reaction mixture was stirred at 25 °C for 12 h. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄, and concentrated in vacuo to give a white solid. This residue was washed with ethyl acetate/hexane and dried in vacuo to give **3** (2.16 g, 65% yield) as a pale yellow solid. The spectroscopic data were

identical to the reported.⁶

Preparation of 6. To a solution of 2-methylquinazolin-4(3H)-one (1.00 g, 6.24 mmol) in DMF (10 mL) was added sodium hydride (60% in mineral oil, 0.30 g, 7.49 mmol) at 0 °C and the reaction mixture was stirred at 0 °C for 1 h. Then, iodomethane (0.974 g, 6.86 mmol) was added. The reaction mixture was stirred at 25 °C for 12 h. Water was added and the crude mixture was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over Na₂SO₄. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give **6** (0.919 g, 84% yield) as a white powder. The spectroscopic data were identical to the reported.⁷


2-(2-Methyl-1H-benzo[d]imidazol-1-yl)-1,1-diphenylethanol (1a).

71%, white powder, TLC (ethyl acetate/methanol = 10/1): R_f = 0.39, ¹H NMR (500 MHz, CDCl₃) δ 1.95 (s, 3H), 2.64 (s, 1H), 4.85 (s, 2H), 7.02–7.12 (m, 2H), 7.16 (ddd, *J* = 8.0, 6.9, and 1.4 Hz, 1H), 7.26–7.40 (m, 10H), 7.61 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 54.1, 78.8, 110.7, 118.6, 121.6, 121.7, 126.4 (4C), 128.1 (2C), 128.6 (4C), 136.5, 142.3, 144.2 (2C), 153.2; IR (KBr, ν / cm⁻¹) 3137, 1614, 1494, 1463, 1397, 1237, 1158, 1071, 1003, 953, 743, 700; HRMS (ESI⁺) Calcd for C₂₂H₂₀N₂ONa (M+Na⁺) 351.1473, Found 351.1461.




1-(4-Methoxyphenyl)-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-1-phenylethanol (1b).

49%, white powder, TLC (ethyl acetate): R_f = 0.38, ¹H NMR (500 MHz, CDCl₃) δ 1.96 (s, 3H), 2.60 (s, 1H), 3.79 (s, 3H), 4.81 (s, 2H), 6.81–6.85 (m, 2H), 7.06 (t, *J* = 8.0 Hz, 1H), 7.11 (d, *J* = 8.6 Hz, 1H), 7.12–7.20 (m, 3H), 7.26–7.35 (m, 5H), 7.61 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 13.6, 54.2, 55.3, 78.5, 110.9, 113.8 (2C), 118.5, 121.6, 121.7, 126.5 (2C), 127.8 (2C), 127.9, 128.4 (2C), 136.4, 136.5, 142.2, 144.4, 153.2, 159.3; IR (KBr, ν / cm⁻¹) 3055, 1607, 1508, 1464, 1399, 1252, 1177, 1033, 835, 744, 703; HRMS (ESI⁺) Calcd for C₂₃H₂₂N₂O₂Na (M+Na⁺) 381.1579, Found 381.1567.




2-(2-Methyl-1H-benzo[d]imidazol-1-yl)-1,1-di-*p*-tolylethanol (1c).

66%, white powder, TLC (ethyl acetate): $R_f = 0.47$, $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 1.91 (s, 3H), 2.34 (s, 6H), 2.73 (s, 1H), 4.79 (s, 2H), 7.05 (dt, $J = 6.9, 1.2$ Hz, 1H), 7.09–7.18 (m, 10H), 7.59 (dd, $J = 7.5, 1.7$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 13.6, 21.0 (2C), 54.1, 78.7, 111.0, 118.5, 121.6 (3C), 126.3 (4C), 129.1 (4C), 136.6, 137.8, 141.4 (2C), 142.3, 153.2; IR (KBr, ν / cm^{-1}) 3158, 1738, 1614, 1509, 1397, 1288, 1235, 1158, 1085, 1004, 813, 740; HRMS (ESI^+) Calcd for $\text{C}_{24}\text{H}_{24}\text{N}_2\text{ONa}$ ($\text{M}+\text{Na}^+$) 379.1786, Found 379.1774.




1,1-Bis(4-fluorophenyl)-2-(2-methyl-1H-benzo[d]imidazol-1-yl)ethanol (1d).

64%, white powder, TLC (ethyl acetate): $R_f = 0.54$, $^1\text{H NMR}$ (500 MHz, $\text{DMSO}-d_6$) δ 2.00 (s, 3H), 4.88 (s, 2H), 6.25 (s, 1H), 6.94 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.02 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.07–7.14 (m, 4H), 7.23 (d, $J = 8.0$ Hz, 1H), 7.31–7.36 (m, 4H), 7.40 (d, $J = 8.0$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO}-d_6$) δ 13.6, 53.4, 77.1, 111.5, 114.5 ($J = 21.5$ Hz, 4C), 117.5, 120.6 (2C), 128.9 ($J = 8.4$ Hz, 4C), 136.6, 141.5 (2C), 141.9, 153.0, 161.3 ($J = 242$ Hz, 2C); IR (KBr, ν / cm^{-1}) 3158, 1604, 1508, 1464, 1399, 1231, 1159, 1078, 1013, 839, 745; HRMS (ESI^+) Calcd for $\text{C}_{22}\text{H}_{18}\text{F}_2\text{N}_2\text{ONa}$ ($\text{M}+\text{Na}^+$) 387.1285, Found 387.1283.




1,1-Bis(4-chlorophenyl)-2-(2-methyl-1H-benzo[d]imidazol-1-yl)ethanol (1e).

61%, white powder, TLC (ethyl acetate/methanol = 10/1): $R_f = 0.47$, $^1\text{H NMR}$ (500 MHz, $\text{DMSO}-d_6$) δ 1.99 (s, 3H), 4.89 (s, 2H), 6.32 (s, 1H), 6.94 (dd, $J = 8.1, 8.1$ Hz, 1H), 7.02 (dd, $J = 8.1, 8.1$ Hz, 1H), 7.24 (d, $J = 8.1$ Hz, 1H), 7.30–7.37 (m, 8H), 7.39 (d, $J = 8.1$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO}-d_6$) δ 13.6, 53.1, 77.1, 111.5, 117.5, 120.6 (2C), 127.8 (4C), 128.7 (4C), 132.1 (2C), 136.5, 141.9, 144.0 (2C), 152.9; IR (KBr, ν / cm^{-1}) 3065, 1736, 1615, 1490, 1464, 1400, 1234, 1159, 1094, 1013, 823, 741; HRMS (ESI^+) Calcd for $\text{C}_{22}\text{H}_{18}\text{Cl}_2\text{N}_2\text{ONa}$ ($\text{M}+\text{Na}^+$) 419.0694, Found 419.0681.




2-Methyl-1-(2-methyl-1*H*-benzo[*d*]imidazol-1-yl)-2-propanol (1f).

87%, pale yellow powder, TLC (ethyl acetate/methanol = 10/1): $R_f = 0.27$, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.34 (s, 6H), 2.41 (s, 1H), 2.60 (s, 3H), 4.07 (s, 2H), 7.14–7.22 (m, 2H), 7.35–7.40 (m, 1H), 7.57–7.62 (m, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 14.5, 28.1 (2C), 54.3, 72.2, 110.5, 118.5, 121.8 (2C), 136.0, 142.1, 153.0; IR (KBr, ν / cm^{-1}) 3174, 2978, 1615, 1403, 1287, 1239, 1186, 1012, 938, 907, 848, 743; HRMS (ESI⁺) Calcd for $\text{C}_{12}\text{H}_{17}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$) 205.1341, Found 205.1333.




1-((2-Methyl-1*H*-benzo[*d*]imidazol-1-yl)methyl)cyclohexanol (1g).

61%, white powder, TLC (hexane/ethyl acetate = 1/1): $R_f = 0.10$, $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 1.15–1.75 (m, 10H), 2.61 (s, 3H), 4.03 (s, 2H), 7.13–7.20 (m, 2H), 7.35–7.40 (m, 1H), 7.55–7.60 (m, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 14.7, 21.3 (2C), 25.5, 35.8 (2C), 54.9, 72.9, 110.5, 118.7, 121.7, 121.8, 136.3, 142.4, 153.1; IR (KBr, ν / cm^{-1}) 3280, 2937, 1522, 1400, 1287, 1248, 1175, 997, 744; HRMS (ESI⁺) Calcd for $\text{C}_{15}\text{H}_{21}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$) 245.1654, Found 245.1644.



2-(2-Methyl-5-(trifluoromethyl)-1*H*-benzo[*d*]imidazol-1-yl)-1,1-diphenylethanol (1h).

43%, white powder, TLC (ethyl acetate): $R_f = 0.50$, $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 2.00 (s, 3H), 3.08 (s, 1H), 4.86 (s, 2H), 7.11 (d, $J = 8.6$ Hz, 1H), 7.24–7.40 (m, 11H), 7.75 (s, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 13.7, 54.2, 78.8, 111.3, 116.1 (d, $J = 4.8$ Hz), 118.6 (d, $J = 3.6$ Hz), 124.0 (q, $J = 32.4$ Hz), 124.9 (q, $J = 271$ Hz), 126.4 (4C), 128.3 (2C), 128.7 (4C), 138.5, 141.6, 144.0 (2C), 155.3; IR (KBr, ν / cm^{-1}) 3136, 1629, 1446, 1327, 1245, 1124, 1068, 890, 811, 755, 698, 622; HRMS (ESI⁺) Calcd for $\text{C}_{23}\text{H}_{19}\text{F}_3\text{N}_2\text{O Na}$ ($\text{M}+\text{Na}^+$) 419.1347, Found 419.1330.




2-(6-Methoxy-2-methyl-1H-benzo[d]imidazol-1-yl)-1,1-diphenylethanol (1i).

23%, white powder, TLC (hexane/ethyl acetate = 3/1): R_f =

0.09, ^1H NMR (400 MHz, CDCl_3) δ 2.01 (s, 3H), 3.00 (s, 1H), 3.67 (s, 3H), 4.80 (s, 2H), 6.44 (d, J = 2.3 Hz, 1H), 6.74 (dd, J = 8.7, 2.3 Hz, 1H), 7.27–7.39 (m, 10H), 7.41 (d, J = 8.7 Hz,

1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.8, 54.2, 55.8, 78.7, 94.5, 110.9, 118.9, 126.5 (4C), 128.1 (2C), 128.5 (4C), 136.6, 136.9, 144.4 (2C), 152.4, 155.9; IR (KBr, ν / cm^{-1}) 3374, 1618, 1485, 1448, 1400, 1216, 1092, 1025, 808, 759, 700, 633; HRMS (ESI^+) Calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{Na}$ ($\text{M}+\text{Na}^+$) 381.1579, Found 381.1578.




2-(2,7-Dimethyl-1H-benzo[d]imidazol-1-yl)-1,1-diphenylethanol (1j).

24%, white powder, TLC (hexane/ethyl acetate = 1/1): R_f = 0.09, ^1H

NMR (400 MHz, CDCl_3) δ 1.74 (s, 3H), 2.54 (s, 3H), 2.76 (s, 1H), 5.06 (s, 2H), 6.87 (d, J = 7.3 Hz, 1H), 7.08 (dd, J = 8.2, 7.3 Hz, 1H), 7.20–7.27 (m, 4H), 7.28–7.35 (m, 6H), 7.49 (d, J = 8.2 Hz, 1H); ^{13}C

NMR (100 MHz, CDCl_3) δ 13.6, 19.5, 54.1, 78.4, 117.0, 121.8 (2C), 125.3, 126.4 (4C), 128.1 (2C), 128.5 (4C), 134.9, 142.8, 144.3 (2C), 153.5; IR (KBr, ν / cm^{-1}) 3062, 1594, 1396, 1294, 1072, 951, 745, 700, 604; HRMS (ESI^+) Calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$) 343.1810, Found 343.1795.




2-(2-Ethyl-1H-benzo[d]imidazol-1-yl)-1,1-diphenylethanol (1k).

83%, white powder, TLC (hexane/ethyl acetate = 1/1): R_f = 0.20, ^1H


NMR (500 MHz, CDCl_3) δ 1.21 (t, J = 7.5 Hz, 3H), 2.21 (q, J = 7.5 Hz, 2H), 2.61 (s, 1H), 4.86 (s, 2H), 7.03–7.10 (m, 2H), 7.11–7.18 (m, 1H), 7.26–7.40 (m, 10H), 7.67 (d, J = 8.0 Hz, 1H); ^{13}C NMR (125

MHz, CDCl_3) δ 11.4, 20.3, 53.6, 78.8, 110.7, 118.8, 121.5, 121.7, 126.4 (4C), 128.1 (2C), 128.5 (4C), 136.5, 142.4, 144.2 (2C), 157.6; IR (KBr, ν / cm^{-1}) 3060, 1509, 1461, 1412, 1069, 743, 700; HRMS (ESI^+) Calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{ONa}$ ($\text{M}+\text{Na}^+$) 365.1630, Found 365.1644.



2-(2-Ethyl-1H-benzo[d]imidazol-1-yl)-1,1-bis(4-fluorophenyl)ethanol (1l).


39%, pale yellow solid, TLC (hexane/ethyl acetate = 1/1): R_f = 0.40, ^1H NMR (500 MHz, CDCl_3) δ 1.25 (t, J = 7.5 Hz, 3H), 2.33 (q, J = 7.5 Hz, 2H), 3.15 (s, 1H), 4.82 (s, 2H), 6.96–7.04 (m, 5H), 7.05 (dd, J = 8.0, 8.0 Hz, 1H), 7.15 (dd, J = 8.0, 8.0 Hz, 1H), 7.24–7.31 (m, 4H), 7.62 (d, J = 8.0 Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 11.5, 20.4, 53.7, 78.1,



110.5, 115.4 (J = 21.5 Hz, 4C), 118.8, 121.7, 121.9, 128.3 (J = 8.4 Hz, 4C), 136.2, 139.9, 142.2 (2C), 157.4, 162.4 (J = 245 Hz, 2C); IR (KBr, ν / cm^{-1}) 3186, 1603, 1506, 1460, 1226, 1159, 1087, 834, 750; HRMS (ESI⁺) Calcd for $\text{C}_{23}\text{H}_{20}\text{F}_2\text{N}_2\text{ONa}$ ($\text{M}+\text{Na}^+$) 401.1441, Found 401.1429.

2-(2-Butyl-1H-benzo[d]imidazol-1-yl)-1,1-diphenylethanol (1m).


42%, white powder, TLC (hexane/ethyl acetate = 1/1): R_f = 0.33, ^1H NMR (500 MHz, CDCl_3) δ 0.83 (t, J = 7.5 Hz, 3H), 1.21 (qt, J = 7.5 Hz, 2H), 1.55–1.64 (m, 2H), 2.07–2.12 (m, 2H), 3.00 (s, 1H), 4.83 (s, 2H), 7.01 (dd, J = 8.0, 8.0 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 7.11 (dd, J = 8.0, 8.0 Hz, 1H), 7.25–7.31 (m, 10H), 7.60



(d, J = 8.0 Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 13.8, 22.6, 26.6, 29.3, 53.6, 78.7, 110.8, 118.7, 121.5, 121.6, 126.4 (4C), 128.0 (2C), 128.5 (4C), 136.3, 142.3, 144.2 (2C), 156.7; IR (KBr, ν / cm^{-1}) 3091, 2929, 1614, 1507, 1461, 1267, 1101, 1073, 1026, 956, 735, 700; HRMS (ESI⁺) Calcd for $\text{C}_{25}\text{H}_{26}\text{N}_2\text{ONa}$ ($\text{M}+\text{Na}^+$) 393.1943, Found 393.1930.

2-(2-Isobutyl-1H-benzo[d]imidazol-1-yl)-1,1-diphenylethanol (1n).

49%, white powder, TLC (ethyl acetate): R_f = 0.61, ^1H NMR (500 MHz, CDCl_3) δ 0.85 (d, J = 6.9 Hz, 6H), 2.04 (d, J = 6.9 Hz, 2H), 2.15–2.24 (m, 1H), 2.76 (s, 1H), 4.88 (s, 2H), 7.03 (dd, J = 8.0, 8.0 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0, 8.0 Hz, 1H), 7.26–7.36 (m, 10H), 7.64 (d, J = 8.0 Hz, 1H); ^{13}C NMR (125 MHz,




CDCl_3) δ 22.6 (2C), 27.4, 35.7, 78.7, 110.7, 118.8, 121.5, 121.6, 126.4 (4C), 128.0 (2C), 128.5 (4C), 136.3, 142.5 (2C), 144.3, 155.9; IR (KBr, ν / cm^{-1}) 3339, 2956, 1508, 1459, 1406, 1327, 1189, 1069, 742, 704, 647; HRMS (ESI⁺) Calcd for $\text{C}_{25}\text{H}_{26}\text{N}_2\text{ONa}$

(M+Na⁺) 393.1943, Found 393.1929.


2-Methyl-4-(2-methyl-1*H*-benzo[*d*]imidazol-1-yl)butan-2-ol (1o).

82%, white powder, TLC (ethyl acetate/methanol = 10/1): R_f = 0.21, ¹H NMR (500 MHz, CDCl₃) δ 1.36 (s, 6H), 1.91 (t, *J* = 8.0 Hz, 2H), 2.61 (s, 3H), 4.27 (t, *J* = 8.0 Hz, 2H), 7.20–7.26 (m, 2H), 7.28–7.34 (m, 1H), 7.66–7.69 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.7, 29.7 (2C), 39.5, 42.6, 69.7, 109.0, 119.0, 121.7, 121.9, 134.9, 142.7, 151.3; IR (KBr, ν / cm⁻¹) 3182, 2962, 1513, 1476, 1413, 1365, 1285, 1233, 1163, 918, 732; HRMS (ESI⁺) Calcd for C₁₃H₁₇N₂O (M+H⁺) 219.1497, Found 219.1488.




2-(2-Methyl-1*H*-benzo[*d*]imidazol-1-yl)phenol (1p).

82%, pale yellow solid, TLC (ethyl acetate): R_f = 0.63, ¹H NMR (500 MHz, CDCl₃) δ 1.82 (s, 3H), 7.00 (dd, *J* = 7.5, 7.5 Hz, 1H), 7.03–7.07 (m, 2H), 7.10 (dd, *J* = 6.9, 6.9 Hz, 1H), 7.15 (dd, *J* = 6.9, 6.9 Hz, 1H), 7.32 (dd, *J* = 8.6, 1.1 Hz, 1H), 7.37 (d, *J* = 8.1 Hz, 1H), 7.45 (ddd, *J* = 8.6, 7.5, and 1.7 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 13.1, 110.7, 118.2, 119.5, 120.4, 122.2, 122.7, 122.9, 128.6, 130.9, 135.3, 141.4, 152.5, 153.6; IR (KBr, ν / cm⁻¹) 3060, 2864, 2696, 2558, 1598, 1517, 1457, 1326, 1295, 1249, 1229, 1021, 752; HRMS (ESI⁺) Calcd for C₁₄H₁₃N₂O (M+H⁺) 225.1028, Found 225.1029.



1-(5-Methyl-1*H*-tetrazol-1-yl)-2-phenyl-2-propanol (1q).


58%, white solid, TLC (hexane/ethyl acetate = 1/1): R_f = 0.14, ¹H NMR (400 MHz, CDCl₃) δ 1.63 (s, 3H), 2.22 (s, 3H), 3.48 (s, 1H), 4.30 (d, *J* = 14.2 Hz, 1H), 4.44 (d, *J* = 14.2 Hz, 1H), 7.20–7.38 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 8.8, 26.8, 57.6, 74.3, 124.8 (2C), 127.9, 128.6 (2C), 143.7, 153.1; IR (KBr, ν / cm⁻¹) 3346, 1527, 1407, 1262, 1221, 1069, 874, 762, 701; HRMS (ESI⁺) Calcd for C₁₁H₁₄N₄ONa (M+Na⁺) 241.1065, Found 241.1062.



3-(2-Hydroxy-2-phenylpropyl)-2-methylquinazolin-4(3H)-one (1r).

51%, white powder, TLC (hexane/ethyl acetate = 1/1): $R_f = 0.21$,

^1H NMR (500 MHz, CDCl_3) δ 1.69 (s, 3H), 2.29 (s, 3H), 4.15 (d, $J = 14.4$ Hz, 1H), 4.31 (s, 1H), 4.68 (d, $J = 14.4$ Hz, 1H), 7.26–7.30 (m, 1H), 7.31–7.37 (m, 2H), 7.43–7.51 (m, 3H), 7.59




(d, $J = 8.6$ Hz, 1H), 7.74 (ddd, $J = 8.6, 6.9,$ and 1.2 Hz, 1H), 8.26 (d, $J = 8.0$ Hz, 1H);

^{13}C NMR (125 MHz, CDCl_3) δ 23.7, 27.6, 55.8, 75.6, 120.0, 125.1, 126.6, 126.7, 127.0, 127.5, 128.5, 134.7, 145.3, 147.1, 154.8, 164.8; IR (KBr, ν / cm^{-1}) 3441, 1661, 1592, 1473, 1384, 1148, 768, 702; HRMS (ESI^+) Calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2\text{Na}$ ($\text{M}+\text{Na}^+$) 317.1266, Found 317.1257.

3-(2-Hydroxy-2-methylpropyl)-2-methylquinazolin-4(3H)-one (1s).

21%, white powder, TLC (hexane/ethyl acetate = 1/2): $R_f = 0.19$,

^1H NMR (500 MHz, CDCl_3) δ 1.31 (s, 6H), 2.70 (s, 3H), 3.57 (s, 1H), 4.25 (s, 2H), 7.45 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.62 (d, $J = 8.0$ Hz, 1H), 7.74 (dd, $J = 8.0, 8.0$ Hz, 1H), 8.23 (d, $J = 8.0$ Hz, 1H);




^{13}C NMR (125 MHz, CDCl_3) δ 24.3, 28.4 (2C), 54.7, 71.9, 120.2, 126.6 (2C), 126.9, 134.6, 147.2, 154.8, 164.2; IR (KBr, ν / cm^{-1}) 3422, 2972, 1649, 1592, 1478, 1386, 1342, 1191, 1138, 979, 780, 694; HRMS (ESI^+) Calcd for $\text{C}_{13}\text{H}_{17}\text{N}_2\text{O}_2$ ($\text{M}+\text{H}^+$) 233.1290, Found 233.1291.

1-(2-Methyl-1H-benzo[d]imidazol-1-yl)-2-propanol (1t).

49%, white powder, TLC (ethyl acetate): $R_f = 0.12$, ^1H NMR (500

MHz, CDCl_3) δ 1.37 (d, $J = 6.3$ Hz, 3H), 2.44 (s, 3H), 3.96 (dd, $J = 14.9, 9.2$ Hz, 1H), 4.02 (dd, $J = 14.9, 3.4$ Hz, 1H), 4.28–4.34 (m, 1H), 6.98 (dd, $J = 8.1, 8.1$ Hz, 1H), 7.09 (dd, $J = 8.1, 8.1$ Hz, 1H), 7.19 (d,




$J = 8.1$ Hz, 1H), 7.23 (d, $J = 8.1$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 14.0, 20.9, 51.5, 65.7, 109.1, 118.3, 121.9 (2C), 134.7, 141.6, 152.1; IR (KBr, ν / cm^{-1}) 3136, 2974, 1411, 1288, 1135, 1083, 754; HRMS (ESI^+) Calcd for $\text{C}_{11}\text{H}_{14}\text{N}_2\text{ONa}$ ($\text{M}+\text{Na}^+$) 213.1004, Found 213.1011.

Typical procedure for copper-catalyzed C(sp³)-H alkoxylation. A mixture of 2-(2-methyl-1*H*-benzo[*d*]imidazol-1-yl)-1,1-diphenylethanol (**1a**, 41.1 mg, 0.125 mmol), CuBr (0.9 mg, 6.3 μ mol), 5,6-dimethyl-1,10-phenanthroline (1.6 mg, 7.7 μ mol), (tBuO)₂ (23.8 mg, 0.163 mmol), and chlorobenzene (1.25 mL) was stirred at 100 °C for 6 h in a sealed tube. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give 3,3-diphenyl-3,4-dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine **2a** (30.8 mg, 75% yield).


3,3-Diphenyl-3,4-dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2a).

yellow solid, TLC (hexane/ethyl acetate = 1/1): R_f = 0.32, ¹H NMR (500 MHz, CDCl₃) δ 4.67 (s, 2H), 4.93 (s, 2H), 7.26–7.32 (m, 12H), 7.35–7.45 (m, 1H), 7.65–7.75 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 49.0, 60.8, 78.9, 108.5, 119.5, 122.2, 122.7, 126.6 (4C), 128.1 (2C), 128.7 (4C), 133.6, 141.1 (2C), 143.1, 147.7; IR (neat, ν / cm⁻¹) 3404, 1617, 1524, 1476, 1453, 1338, 1227, 1076, 745, 699; HRMS (ESI⁺) Calcd for C₂₂H₁₉N₂O (M+H⁺) 327.1497, Found 327.1499.



3-(4-Methoxyphenyl)-3-phenyl-3,4-dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2b).


Reaction conditions: CuBr (5.0 mol%), 5,6-dimethyl-1,10-phenanthroline (6.0 mol%), (tBuO)₂ (1.3 equiv), 100 °C, 6 h. 71%, yellow solid, purification: silica gel column chromatography (hexane/ethyl acetate = 1/1), TLC (hexane/ethyl acetate = 1/1): R_f = 0.36, ¹H NMR (500 MHz, CDCl₃) δ 3.76 (s, 3H), 4.58 (d, *J* = 12.9 Hz, 1H), 4.68 (d, *J* = 12.9 Hz, 1H), 4.87 (d, *J* = 16.4 Hz, 1H), 4.95 (d, *J* = 16.4 Hz, 1H), 6.81 (d, *J* = 8.6 Hz, 2H), 7.20 (d, *J* = 8.6 Hz, 2H), 7.23–7.35 (m, 7H), 7.40–7.46 (m, 1H), 7.67–7.73 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 49.2, 55.2, 60.7, 78.7, 108.5, 114.0 (2C), 119.5, 122.2, 122.7, 126.5 (2C), 128.0, 128.1 (2C), 128.6 (2C), 132.7, 133.6, 141.8, 143.1, 147.8, 159.3; IR (neat, ν / cm⁻¹) 2360, 1510, 1454, 1249, 1179, 1076, 747; HRMS (ESI⁺) Calcd for C₂₃H₂₁N₂O₂ (M+H⁺) 357.1603, Found 357.1594.



3,3-Di-*p*-tolyl-3,4-dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2c).

Reaction conditions: CuBr (5.0 mol%), 5,6-dimethyl-1,10-phenanthroline (6.0 mol%), (*t*BuO)₂ (1.3 equiv), 100 °C, 6 h.

55%, pale yellow solid, purification: silica gel column chromatography (hexane/ethyl acetate = 1/1), TLC




(hexane/ethyl acetate = 1/1): $R_f = 0.43$, ¹H NMR (500 MHz, CDCl₃) δ 2.31 (s, 6H), 4.62 (s, 2H), 4.91 (s, 2H), 7.11 (d, $J = 8.0$ Hz, 4H), 7.20 (d, $J = 8.0$ Hz, 4H), 7.27–7.32 (m, 2H), 7.40–7.47 (m, 1H), 7.69–7.75 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 21.0 (2C), 49.2, 60.7, 78.7, 108.5, 119.5, 122.1 (2C), 122.6, 126.5 (4C), 129.3 (4C), 133.6, 137.9, 138.3 (2C), 143.1, 147.9; IR (neat, ν / cm^{-1}) 2920, 1617, 1510, 1454, 1227, 1087, 810, 744; HRMS (ESI⁺) Calcd for C₂₄H₂₃N₂O (M+H⁺) 355.1810, Found 355.1804.

3,3-Bis(4-fluorophenyl)-3,4-dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2d).

Reaction conditions: CuBr (5.0 mol %), 5,6-dimethyl-1,10-phenanthroline (6.0 mol%), (*t*BuO)₂ (1.3 equiv), 100 °C, 6 h.

81%, pale yellow oil, purification: silica gel column chromatography (hexane/ethyl acetate = 1/1), TLC




(hexane/ethyl acetate = 1/1): $R_f = 0.49$, ¹H NMR (500 MHz, CDCl₃) δ 4.56 (s, 2H), 4.85 (s, 2H), 6.95 (dd, $J = 8.6, 8.6$ Hz, 4H), 7.15–7.30 (m, 6H), 7.33–7.40 (m, 1H), 7.61–7.68 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 49.2, 60.8, 78.2, 108.5, 115.7 (d, $J = 21.5$ Hz, 4C), 119.6, 122.4, 122.9, 128.5 (d, $J = 8.4$ Hz, 4C), 133.4, 136.8 (d, $J = 3.6$ Hz, 2C), 143.1, 147.2, 162.4 (d, $J = 247$ Hz, 2C); IR (neat, ν / cm^{-1}) 1605, 1508, 1454, 1372, 1228, 1160, 1085, 1014, 836, 745; HRMS (ESI⁺) Calcd for C₂₂H₁₇F₃N₂O (M+H⁺) 363.1309, Found 363.1297.

3,3-Bis(4-chlorophenyl)-3,4-dihydro-1H-benzo[4,5]imidazo[2,1-c][1,4]oxazine (2e).

Reaction conditions: CuBr (5.0 mol%), 5,6-dimethyl-1,10-phenanthroline (6.0 mol%), (^tBuO)₂ (1.3 equiv), 100 °C, 6 h.

81%, pale yellow solid, purification: silica gel column chromatography (hexane/ ethyl acetate = 1/1), TLC (hexane/ethyl acetate = 1/1): R_f = 0.46, ¹H NMR (500 MHz,




CDCl₃) δ 4.60 (s, 2H), 4.91 (s, 2H), 7.23 (d, *J* = 8.6 Hz, 4H), 7.29 (d, *J* = 8.6 Hz, 4H), 7.30–7.35 (m, 2H), 7.41–7.46 (m, 1H), 7.70–7.75 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 48.9, 60.9, 78.2, 108.5, 119.7, 122.5 (2C), 123.0, 128.0 (4C), 129.0 (4C), 133.4, 134.4, 139.2 (2C), 143.1, 147.1; IR (neat, ν / cm⁻¹) 1489, 1454, 1401, 1227, 1090, 1012, 831, 746; HRMS (ESI⁺) Calcd for C₂₂H₁₇Cl₂N₂O (M+H⁺) 395.0718, Found 395.0700.

3,3-Dimethyl-3,4-dihydro-1H-benzo[4,5]imidazo[2,1-c][1,4]oxazine (2f).

Reaction conditions: CuBr (5.0 mol%), 4,7-dimethoxy-1,10-phenanthroline (6.0 mol%), (^tBuO)₂ (1.3 equiv), 100 °C, 4 h.

55%, yellow solid, purification: silica gel column chromatography




(hexane/ethyl acetate = 1/2), TLC (hexane/ethyl acetate = 1/2): R_f = 0.19, ¹H NMR (500 MHz, CDCl₃) δ 1.44 (s, 6H), 3.96 (s, 2H), 5.05 (s, 2H), 7.26–7.35 (m, 3H), 7.74 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 24.3 (2C), 51.2, 59.9, 70.6, 108.6, 119.3, 122.0, 122.5, 134.1, 143.0, 147.2; IR (neat, ν / cm⁻¹) 3391, 2976, 1740, 1477, 1453, 1386, 1271, 1215, 1157, 1081, 867, 744; HRMS (ESI⁺) Calcd for C₁₂H₁₅N₂O (M+H⁺) 203.1184, Found 203.1182.

1,4-Dihydrospiro[benzo[4,5]imidazo[2,1-c][1,4]oxazine-3,1'-cyclohexane] (2g).

Reaction conditions: CuBr (5.0 mol%), 5,6-dimethyl-1,10-phenanthroline (6.0 mol%), (^tBuO)₂ (2.0 equiv), 100 °C, 4 h.

52%, pale yellow solid, purification: silica gel column




chromatography (hexane/ethyl acetate = 1/1), TLC (hexane/ethyl acetate = 1/1): R_f =

0.39, ^1H NMR (500 MHz, CDCl_3) δ 1.32–1.44 (m, 1H), 1.47–1.60 (m, 4H), 1.65–1.75 (m, 3H), 1.89–1.95 (m, 2H), 3.92 (s, 2H), 5.02 (s, 2H), 7.23–7.33 (m, 3H), 7.72 (d, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 21.4 (2C), 25.7, 32.8 (2C), 50.8, 59.1, 71.5, 108.7, 119.3, 122.0, 122.4, 134.2, 143.1, 147.7; IR (neat, ν / cm^{-1}) 2935, 1740, 1477, 1454, 1338, 1228, 1157, 1079, 887, 744; HRMS (ESI^+) Calcd for $\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$) 243.1497, Found 243.1500.

3,3-Diphenyl-8-(trifluoromethyl)-3,4-dihydro-1H-benzo[4,5]imidazo[2,1-c][1,4]oxazine (2h).


Reaction conditions: CuBr (5.0 mol%), 5,6-dimethyl-1,10-phenanthroline (6.0 mol%), $(^t\text{BuO})_2$ (1.3 equiv), 100 °C, 6 h.



45%, pale yellow solid, purification: silica gel column chromatography (hexane/ethyl acetate = 2/1), TLC (hexane/ethyl acetate = 1/1): $R_f = 0.80$, ^1H NMR (500 MHz, CDCl_3) δ 4.70 (s, 2H), 4.96 (s, 2H), 7.27–7.35 (m, 10H), 7.53 (d, $J = 8.4$ Hz, 1H), 7.59 (d, $J = 8.4$ Hz, 1H), 7.99 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 49.2, 60.7, 78.9, 108.9, 117.2 (d, $J = 3.6$ Hz), 119.3 (d, $J = 3.6$ Hz), 127.7 (q, $J = 272$ Hz), 125.3 (q, $J = 32.4$ Hz), 126.5 (4C), 128.3 (2C), 128.8 (4C), 135.6, 140.8 (4C), 142.6, 149.8; IR (neat, ν / cm^{-1}) 1628, 1448, 1330, 1161, 1117, 1051, 913, 755, 699, 671; HRMS (ESI^+) Calcd for $\text{C}_{23}\text{H}_{17}\text{F}_3\text{N}_2\text{ONa}$ ($\text{M}+\text{Na}^+$) 417.1191, Found 417.1185.

7-Methoxy-3,3-diphenyl-3,4-dihydro-1H-benzo[4,5]imidazo[2,1-c][1,4]oxazine (2i).

Reaction conditions: CuBr (10 mol%), 5,6-dimethyl-1,10-phenanthroline (12 mol%), $(^t\text{BuO})_2$ (2.6 equiv), 100 °C, 6 h.



70%, pale yellow solid, purification: silica gel column chromatography (hexane/ethyl acetate = 1/1), TLC (hexane/ethyl acetate = 3/1): $R_f = 0.20$, ^1H NMR (500 MHz, CDCl_3) δ 3.90 (s, 3H), 4.61 (s, 2H), 4.89 (s, 2H), 6.92 (d, $J = 2.3$ Hz, 1H), 6.94 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.26–7.35 (m, 10H), 7.58 (d, $J = 8.6$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 49.1, 55.9, 60.8, 78.9, 92.6, 111.5, 119.9, 126.6 (4C), 128.1 (2C), 128.6 (4C), 134.1, 137.5, 141.2 (2C), 146.7, 156.3; IR (neat, ν / cm^{-1})

2955, 1624, 1451, 1355, 1274, 1211, 1147, 1075, 816, 754, 699, 639; HRMS (ESI⁺)
Calcd for C₂₃H₂₁N₂O (M+H⁺) 357.1603, Found 357.1591.

6-Methyl-3,3-diphenyl-3,4-dihydro-1H-benzo[4,5]imidazo[2,1-c][1,4]oxazine (2j).

Reaction conditions: CuBr (5.0 mol%), 5,6-dimethyl-1,10-phenanthroline (6.0 mol%),
(^tBuO)₂ (1.3 equiv), 100 °C, 6 h.

80%, pale yellow solid, purification: silica gel column

chromatography (hexane/ethyl acetate = 1/1), TLC (hexane/ethyl

acetate = 1/1): R_f = 0.39, ¹H NMR (500 MHz, CDCl₃) δ 2.80 (s, 3H),

4.92 (s, 2H), 4.99 (s, 2H), 7.01 (d, *J* = 6.9 Hz, 1H), 7.16 (t, *J* = 8.0


Hz, 1H), 7.27–7.40 (m, 10H), 7.54 (d, *J* = 8.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃)

δ 18.5, 51.6, 60.9, 78.9, 117.4, 120.9, 122.5, 124.5, 126.8 (4C), 128.1 (2C), 128.7 (4C),

132.5, 141.2 (2C), 143.2, 147.5; IR (neat, ν / cm⁻¹) 1651, 1526, 1474, 1448, 1336, 1272,

1218, 1081, 748, 699, 650, 608; HRMS (ESI⁺) Calcd for C₂₃H₂₁N₂O (M+H⁺) 341.1654,

Found 341.1641.



1-Methyl-3,3-diphenyl-3,4-dihydro-1H-benzo[4,5]imidazo[2,1-c][1,4]oxazine (2k).

Reaction conditions: CuBr (10 mol%),

4,7-dimethoxy-1,10-phenanthroline (12 mol%), (^tBuO)₂ (2.6 equiv),

100 °C, 4 h.

70%, pale yellow solid, purification: silica gel column

chromatography (hexane/ethyl acetate = 2/1), TLC (hexane/ethyl acetate = 1/1): R_f =

0.53, ¹H NMR (500 MHz, CDCl₃) δ 1.86 (d, *J* = 6.6 Hz, 3H), 4.28 (d, *J* = 12.6 Hz, 1H),

4.74 (q, *J* = 6.6 Hz, 1H), 5.09 (d, *J* = 12.6 Hz, 1H), 7.20–7.29 (m, 5H), 7.30–7.36 (m,


3H), 7.40 (t, *J* = 7.5 Hz, 2H), 7.44–7.50 (m, 3H), 7.79 (d, *J* = 8.0 Hz, 1H); ¹³C NMR

(125 MHz, CDCl₃) δ 19.6, 49.2, 66.7, 78.6, 108.7, 119.6, 122.3, 122.7, 125.5 (2C),

127.6 (2C), 127.7, 128.2, 128.4 (2C), 128.8 (2C), 133.7, 139.1, 143.0, 144.4, 151.8; IR

(neat, ν / cm⁻¹) 3420, 1455, 1101, 748, 699; HRMS (ESI⁺) Calcd for C₂₃H₂₁N₂O


(M+H⁺) 341.1654, Found 341.1656.



3,3-Bis(4-fluorophenyl)-1-methyl-3,4-dihydro-1H-benzo[4,5]imidazo[2,1-c][1,4]oxazine (2l).

Reaction conditions: CuBr (10 mol%), 4,7-dimethoxy-1,10-phenanthroline (12 mol%), (^tBuO)₂ (2.6 equiv), 100 °C, 4 h.

67%, yellow oil, purification: silica gel column chromatography (hexane/ethyl acetate = 1/1), TLC




(hexane/ethyl acetate = 1/1): R_f = 0.55, ¹H NMR (500 MHz,

CDCl₃) δ 1.82 (d, *J* = 6.3 Hz, 3H), 4.23 (d, *J* = 12.6 Hz, 1H), 4.66 (q, *J* = 6.3 Hz, 1H), 4.98 (d, *J* = 12.6 Hz, 1H), 6.94 (dd, *J* = 8.6, 8.6 Hz, 2H), 7.06 (dd, *J* = 8.6, 8.6 Hz, 2H), 7.16 (dd, *J* = 8.6, 5.2 Hz, 2H), 7.29–7.36 (m, 2H), 7.37–7.47 (m, 3H), 7.73–7.80 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 19.6, 49.4, 66.8, 78.0, 108.6, 115.3 (*J* = 21.5 Hz, 2C), 115.9 (*J* = 21.5 Hz, 2C), 119.8, 122.5, 122.9, 127.4 (*J* = 8.4 Hz, 2C), 129.5 (*J* = 8.4 Hz, 2C), 133.6, 134.8 (*J* = 3.6 Hz), 140.0 (*J* = 3.6 Hz), 143.0, 151.4, 162.2 (*J* = 246 Hz), 162.4 (*J* = 248 Hz); IR (neat, ν / cm⁻¹) 1606, 1507, 1455, 1373, 1319, 1230, 1159, 1103, 836, 748; HRMS (ESI⁺) Calcd for C₂₃H₁₉F₂N₂O (M+H⁺) 377.1465, Found 377.1451.

3,3-Diphenyl-1-propyl-3,4-dihydro-1H-benzo[4,5]imidazo[2,1-c][1,4]oxazine (2m).

Reaction conditions: CuBr (10 mol%), 4,7-dimethoxy-1,10-phenanthroline (12 mol%), (^tBuO)₂ (2.6 equiv), 100 °C, 4 h.




71%, yellow oil, purification: silica gel column

chromatography (hexane/ethyl acetate = 1/1), TLC (hexane/ethyl acetate = 1/1): R_f = 0.67, ¹H NMR (500 MHz, CDCl₃) δ 1.06 (t, *J* = 7.5 Hz, 3H), 1.73 (q, *J* = 7.5 Hz, 2H), 2.13–2.22 (m, 1H), 2.30–2.40 (m, 1H), 4.28 (d, *J* = 12.6 Hz, 1H), 4.67 (d, *J* = 7.5 Hz, 1H), 5.10 (d, *J* = 12.6 Hz, 1H), 7.21–7.31 (m, 5H), 7.32–7.44 (m, 5H), 7.45–7.53 (m, 3H), 7.78 (d, *J* = 7.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 13.8, 18.3, 35.8, 49.0, 69.9, 78.4, 108.6, 119.6, 122.2, 122.6, 125.4 (2C), 127.5 (2C), 127.7, 128.2, 128.4 (2C), 128.8, 133.7, 139.1, 143.1, 144.6, 151.2; IR (neat, ν / cm⁻¹) 2959, 1518, 1474, 1455, 1428, 1375, 1327, 1218, 1072, 744, 699; HRMS (ESI⁺) Calcd for C₂₅H₂₅N₂O (M+H⁺) 369.1967, Found 369.1956.

1-Isopropyl-3,3-diphenyl-3,4-dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2n).

Reaction conditions: CuBr (10 mol%),
4,7-dimethoxy-1,10-phenanthroline (12 mol%), (^tBuO)₂ (2.6 equiv),
100 °C, 4 h.




41%, yellow oil, purification: silica gel column chromatography

(hexane/ethyl acetate = 1/1), TLC (hexane/ethyl acetate = 1/1): R_f = 0.66, ¹H NMR (500 MHz, CDCl₃) δ 1.04 (d, *J* = 6.9 Hz, 3H), 1.28 (d, *J* = 6.9 Hz, 3H), 2.70–2.80 (m, 1H), 4.23 (d, *J* = 12.9 Hz, 1H), 4.57 (s, 1H), 5.06 (d, *J* = 12.9 Hz, 1H), 7.15–7.25 (m, 5H), 7.27–7.42 (m, 5H), 7.44–7.50 (m, 3H), 7.75 (d, *J* = 6.9 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 16.4, 19.0, 32.4, 49.0, 74.5, 78.2, 108.5, 119.6, 122.2, 122.6, 125.4 (2C), 127.4 (2C), 127.7, 128.2, 128.4 (2C), 128.8 (2C), 133.7, 139.0, 143.1, 144.7, 150.7; IR (neat, ν / cm⁻¹) 2964, 1454, 1227, 1064, 1024, 753, 699; HRMS (ESI⁺) Calcd for C₂₅H₂₅N₂O (M+H⁺) 369.1967, Found 369.1951.

3,3-Dimethyl-1,3,4,5-tetrahydrobenzo[4,5]imidazo[2,1-*c*][1,4]oxazepine (2o).

Reaction conditions: CuBr (5.0 mol%),
5,6-dimethyl-1,10-phenanthroline (6.0 mol%), (^tBuO)₂ (1.3 equiv),
100 °C, 12 h.




21%, yellow solid, purification: silica gel column

chromatography (hexane/ethyl acetate = 1/3), TLC (hexane/ethyl acetate = 1/2): R_f = 0.25, ¹H NMR (500 MHz, CDCl₃) δ 1.41 (s, 6H), 2.21 (t, *J* = 5.2 Hz, 2H), 4.24 (t, *J* = 5.2 Hz, 2H), 4.94 (s, 2H), 7.21–7.34 (m, 3H), 7.70 (d, *J* = 6.9 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 26.3 (2C), 38.7, 39.8, 59.9, 75.7, 108.9, 119.5, 122.0, 122.3, 135.5, 142.5, 153.9; IR (neat, ν / cm⁻¹) 1455, 1374, 1085, 747; HRMS (ESI⁺) Calcd for C₁₃H₁₆N₂O (M+H⁺) 217.1341, Found 217.1350.

6*H*-Benzo[*b*]benzo[4,5]imidazo[1,2-*d*][1,4]oxazine (2p).

Reaction conditions: CuBr (20 mol%),
5,6-dimethyl-1,10-phenanthroline (24 mol%), (^tBuO)₂ (1.3 equiv),
100 °C, 12 h.




59%, yellow solid, purification: silica gel column chromatography

(hexane/ethyl acetate = 1/3), TLC (ethyl acetate): $R_f = 0.72$, ^1H NMR (500 MHz, CDCl_3) δ 5.38 (s, 2H), 7.19–7.22 (m, 3H), 7.34–7.42 (m, 2H), 7.80–7.88 (m, 2H), 7.90 (d, $J = 6.9$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 64.5, 111.3, 116.2, 118.4, 120.6, 123.2, 123.3, 124.0, 126.0, 126.4, 131.3, 143.7, 146.4, 146.6; IR (neat, ν / cm^{-1}) 1621, 1550, 1504, 1465, 1399, 1343, 1237, 1215, 1031, 738; HRMS (ESI^+) Calcd for $\text{C}_{14}\text{H}_{11}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$) 223.0871, Found 223.0871.

6-Methyl-6-phenyl-6,8-dihydro-5H-tetrazolo[5,1-c][1,4]oxazine (2q).


Reaction conditions: CuBr_2 (10 mol%), 4,7-dimethoxy-1,10-phenanthroline (12 mol%), $(^t\text{BuO})_2$ (2.6 equiv), 100 °C, 6 h.



44%, pale yellow solid, purification: silica gel column chromatography (hexane/ethyl acetate = 1/1), TLC (hexane/ethyl acetate = 1/1): $R_f = 0.45$, ^1H NMR (500 MHz, CDCl_3) δ 1.70 (s, 3H), 4.47 (d, $J = 13.4$ Hz, 1H), 4.74 (d, $J = 16.6$ Hz, 1H), 5.09 (d, $J = 13.4$ Hz, 1H), 5.11 (d, $J = 16.6$ Hz, 1H), 7.27–7.40 (m, 5H); ^{13}C NMR (125 MHz, CDCl_3) δ 27.5, 51.8, 57.9, 75.5, 125.3, 128.8, 129.2, 138.5, 149.1; IR (neat, ν / cm^{-1}) 2981, 1448, 1380, 1346, 1295, 1158, 1065, 836, 765, 701; HRMS (ESI^+) Calcd for $\text{C}_{11}\text{H}_{12}\text{N}_4\text{ONa}$ ($\text{M}+\text{Na}^+$) 239.0909, Found 239.0915.

3-Methyl-3-phenyl-3,4-dihydro-[1,4]oxazino[3,4-b]quinazolin-6(1H)-one (2r).


Reaction conditions: CuBr_2 (5.0 mol%), 4,7-dimethoxy-1,10-phenanthroline (6.0 mol%), $(^t\text{BuO})_2$ (1.3 equiv), 100 °C, 12 h.



49%, pale yellow solid, purification: silica gel column chromatography (hexane/ethyl acetate = 1/2), TLC (hexane/ethyl acetate = 1/1): $R_f = 0.39$, ^1H NMR (500 MHz, CDCl_3) δ 1.66 (s, 3H), 3.96 (d, $J = 14.4$ Hz, 1H), 4.58 (d, $J = 16.9$ Hz, 1H), 4.82 (d, $J = 16.9$ Hz, 1H), 5.01 (d, $J = 14.4$ Hz, 1H), 7.24–7.29 (m, 1H), 7.30–7.38 (m, 4H), 7.45 (td, $J = 7.4, 1.2$ Hz, 1H), 7.53 (d, $J = 8.0$ Hz, 1H), 7.71 (td, $J = 6.9, 1.1$ Hz, 1H), 8.29 (dd, $J = 8.0, 1.1$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 28.7, 46.8, 63.4, 75.7, 120.3, 125.3 (2C), 126.5, 126.6, 126.8, 128.1, 129.1 (2C), 134.6, 140.3, 147.1, 150.8, 161.2; IR (neat, ν / cm^{-1}) 3442, 1673, 1600, 1469, 1335, 1088, 765, 699; HRMS (ESI^+) Calcd for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_2\text{Na}$ ($\text{M}+\text{Na}^+$) 315.1109, Found 315.1099.

3,3-Dimethyl-3,4-dihydro-[1,4]oxazino[3,4-*b*]quinazolin-6(1*H*)-one (2s).


Reaction conditions: CuBr₂ (5.0 mol%), 4,7-dimethoxy-1,10-phenanthroline (6.0 mol%), (^tBuO)₂ (1.3 equiv), 100 °C, 12 h.



50%, white solid, purification: silica gel column chromatography (hexane/ethyl acetate = 1/2), TLC (hexane/ethyl acetate = 1/2): R_f = 0.53, ¹H NMR (400 MHz, CDCl₃) δ 1.39 (s, 6H), 3.94 (s, 2H), 4.78 (s, 2H), 7.47 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.75 (dd, *J* = 8.0 Hz, 1H), 8.29 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 24.7 (2C), 49.3, 62.9, 71.3, 120.5, 126.5, 126.7, 126.8, 134.6, 147.2, 151.0, 161.5; IR (neat, ν / cm⁻¹) 3420, 1671, 1596, 1475, 1381, 1323, 1215, 1163, 1102, 770, 697; HRMS (ESI⁺) Calcd for C₁₃H₁₄N₂O₂Na (M+Na⁺) 253.0953, Found 253.0956.

3-Methyl-3,4-dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2t).


Reaction conditions: CuBr₂ (10 mol%), 4,7-dimethoxy-1,10-phenanthroline (12 mol%), (^tBuO)₂ (2.6 equiv), 100 °C, 4 h.



40%, pale yellow solid, purification: silica gel column chromatography (hexane/ethyl acetate = 1/2), TLC (hexane/ethyl acetate = 1/2): R_f = 0.18, ¹H NMR (500 MHz, CDCl₃) δ 1.47 (d, *J* = 6.3 Hz, 3H), 3.81 (dd, *J* = 10.4, 10.4 Hz, 1H), 4.05-4.15 (m, 2H), 4.96 (d, *J* = 16.1 Hz, 1H), 5.15 (d, *J* = 16.1 Hz, 1H), 7.23-7.33 (m, 3H), 7.71 (dd, *J* = 6.3, 2.3 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 18.7, 47.9, 64.9, 70.1, 108.7, 119.4, 122.3, 122.6, 133.8, 142.7, 147.8; IR (neat, ν / cm⁻¹) 2872, 1480, 1424, 1329, 1280, 1097, 862, 744; HRMS (ESI⁺) Calcd for C₁₁H₁₃N₂O (M+H⁺) 189.1028, Found 189.1021.

3,4-Dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2u).

Reaction conditions: CuBr (10 mol%), 5,6-dimethyl-1,10-phenanthroline (12 mol%), (^tBuO)₂ (2.6 equiv), 100 °C, 4 h.



24%, pale yellow solid, purification: silica gel column chromatography (hexane/ethyl acetate = 1/3), TLC (hexane/ethyl acetate = 1/1): R_f = 0.10, ¹H NMR (500 MHz,


CDCl₃) δ 4.15-4.23 (m, 4H), 5.04 (s, 2H), 7.27-7.36 (m, 3H), 7.70-7.75 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 42.0, 64.0, 65.5, 108.7, 119.5, 122.3, 122.6, 134.0, 142.7, 147.8; IR (neat, ν / cm⁻¹) 2923, 1523, 1451, 1373, 1321, 1096, 984, 920, 878, 745; HRMS (ESI⁺) Calcd for C₁₀H₁₁N₂O (M+H⁺) 175.0871, Found 175.0865.

Gram-scale procedure for copper-catalyzed C(sp³)-H alkoxylation. A mixture of 2-(2-methyl-1*H*-benzo[*d*]imidazol-1-yl)-1,1-diphenylethanol (**1a**, 1.64 g, 5.00 mmol), CuBr (35.9 mg, 0.25 mmol), 5,6-dimethyl-1,10-phenanthroline (62.5 mg, 0.300 mmol), (*t*BuO)₂ (0.950 g, 6.50 mmol), and chlorobenzene (50 mL) was stirred at 100 °C for 6 h. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give 3,3-diphenyl-3,4-dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine **2a** (1.37 g, 84% yield).

Typical procedure for intermolecular alkoxylation. A mixture of 1,2-dimethyl-1*H*-benzo[*d*]imidazole^[5] (**3**, 18.3 mg, 0.125 mmol), 2-phenylethyl alcohol (**4b**, 30.5 mg, 0.250 mmol), CuBr (3.6 mg, 25.0 μ mol), 5,6-dimethyl-1,10-phenanthroline (6.2 mg, 30.0 μ mol), (*t*BuO)₂ (73.3 mg, 0.501 mmol), and chlorobenzene (2.50 mL) was stirred at 100 °C for 3 h in a sealed tube. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (hexane/ethyl acetate = 1/2) to give **5b** (12.2 mg, 37% yield).

2-(Butoxymethyl)-1-methyl-1*H*-benzo[*d*]imidazole (5a).

33%, yellow oil, purification: silica gel column chromatography (hexane/ethyl acetate = 1/2), TLC (hexane/ethyl acetate = 1/1): R_f = 0.30, ¹H NMR (500 MHz,




CDCl₃) δ 0.89 (t, *J* = 7.5 Hz, 3H), 1.35 (qt, *J* = 7.5, 7.5 Hz, 2H), 1.54–1.61 (m, 2H), 3.50 (t, *J* = 6.6 Hz, 2H), 3.86 (s, 3H), 4.80 (s, 2H), 7.26–7.33 (m, 2H), 7.35 (d, *J* = 7.5 Hz, 1H), 7.75 (d, *J* = 8.1 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 13.8, 19.2, 27.4, 31.6, 65.7, 70.5, 109.2, 119.9, 122.1, 122.9, 136.3, 142.2, 191.0; IR (KBr, ν / cm⁻¹) 2957, 2870, 1617, 1477, 1398, 1333, 1238, 1096, 1005, 741; HRMS (ESI⁺) Calcd for C₁₃H₁₉N₂O (M+H⁺) 219.1497, Found 219.1501.

1-Methyl-2-(phenethoxymethyl)-1H-benzo[d]imidazole (5b).

37%, yellow solid, purification: silica gel column

chromatography (hexane/ethyl acetate = 1/1), TLC

(hexane/ethyl acetate = 1/1): $R_f = 0.13$, $^1\text{H NMR}$ (400 MHz,




CDCl_3) δ 2.85 (t, $J = 6.7$ Hz, 2H), 3.56 (s, 3H), 3.71 (t, $J = 6.7$ Hz, 2H), 4.77 (s, 2H), 7.08–7.31 (m, 8H), 7.71 (d, $J = 7.8$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 29.8, 36.1, 65.7, 71.1, 109.3, 119.9, 122.1, 122.9, 126.2, 128.3 (2C), 128.8 (2C), 136.2, 138.8, 142.1, 150.6; IR (neat, ν / cm^{-1}) 2936, 1705, 1477, 1397, 1333, 1097, 743, 700; HRMS (ESI⁺) Calcd for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$) 267.1497, Found 267.1496.

3-Methyl-2-(phenethoxymethyl)quinazolin-4(3H)-one (7).

30%, yellow solid, purification: silica gel column

chromatography (hexane/ethyl acetate = 1/1), TLC

(hexane/ethyl acetate = 1/1): $R_f = 0.45$, $^1\text{H NMR}$ (500 MHz,



CDCl_3) δ 2.92 (t, $J = 8.6$ Hz, 2H), 3.52 (s, 3H), 3.82 (t, $J =$


8.6 Hz, 4.61 (s, 2H), 7.15–7.29 (m, 5H), 7.49 (dt, $J = 1.8, 8.6$ Hz, 1H), 7.67 (d, $J = 10.9$ Hz, 1H), 7.74 (dt, $J = 1.7, 10.9$ Hz, 1H), 8.27 (d, $J = 10.3$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 30.4, 36.2, 71.7, 72.7, 120.9, 126.4, 126.7, 127.2, 127.3, 128.4 (2C), 128.8 (2C), 134.1, 138.4, 146.8, 152.7, 162.4; IR (neat, ν / cm^{-1}) 2924, 1679, 1603, 1474, 1367, 1107, 776, 698, 611; HRMS (ESI⁺) Calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2$ ($\text{M}+\text{H}^+$) 295.1447, Found 295.1433.

1,1-Diphenyl-2-(2-(((2,2,6,6-tetramethyl-1-piperidinyloxy)methyl)-1H-benzo[d]imidazol-1-yl)ethanol (8).

45%, pale yellow solid, purification: silica gel column

chromatography (hexane/ethyl acetate = 1/1), TLC

(hexane/ethyl acetate = 1/1): $R_f = 0.45$, $^1\text{H NMR}$ (500 MHz,



CDCl_3) δ 0.92 (s, 6H), 1.14 (s, 6H), 1.20–1.55 (m, 6H), 3.88

(s, 1H), 4.76 (s, 2H), 5.13 (s, 2H), 6.39 (d, $J = 7.8$ Hz, 1H),

6.89 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.10 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.20–7.39 (m, 10H), 7.67


(d, $J = 7.8$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 16.9, 20.2 (4C), 33.1 (2C), 39.8

(2C), 54.9, 60.1, 72.6, 111.2, 119.6, 121.7, 122.4, 126.4 (4C), 127.6 (2C), 128.4 (4C),

136.1, 142.0, 145.4 (2C), 151.2; IR (neat, ν / cm^{-1}) 3191, 2932, 1463, 1415, 1361, 1242, 1132, 1030, 752, 700; HRMS (ESI⁺) Calcd for C₃₁H₃₈N₃O₂ (M+H⁺) 484.2964, Found 484.2986.

Another possible mechanism for the alkoxylation reaction: (1) oxidation of a copper catalyst CuBr (or CuBr₂) by (^tBuO)₂;⁸ (2) formation of an alkoxy copper intermediate via the elimination of ^tBuOH (in the case of CuBr₂: ^tBuOH or HBr);⁹ (3) formation of a metalacyclic intermediate via the elimination of ^tBuOH (in the case of CuBr₂: ^tBuOH or HBr) (C-H bond activation); and (4) reductive elimination to give the product and regenerate CuBr.



Scheme S1 Proposed mechanism for the catalytic benzylic C(sp³)-H alkoxylation.







Asymmetric alkoxylation reaction. A mixture of 2-(2-ethyl-1*H*-benzo[*d*]imidazol-1-yl)-1,1-bis(4-fluorophenyl)ethanol (**11**, 23.7 mg, 62.6 μmol), CuBr₂ (1.4 mg, 6.3 μmol), (-)-spartaine (1.8 mg, 7.7 μmol), (^tBuO)₂ (23.8 mg, 0.163 mmol), and chlorobenzene (1.25 mL) was stirred at 100 °C for 12 h in a sealed tube. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give **21*** (3.4 mg, 14% yield). The enantiomeric excesses (11% *ee*) were determined by HPLC analysis on a CHIRAPAK AD-H column (hexane/ethanol = 12/1) with retention time; 6.92 min (minor), 34.4 min (major).



References



1. T. Yamashita, S. Yamada, Y. Yamazaki, H. Tanaka, *Synth. Commun.*, 2009, **39**, 2982.
2. J. A. Ciaccio, A. L. Drahus, R. M. Meis, C. T. Tingle, M. Smrtka, R. Geneste, *Synth. Commun.*, 2003, **33**, 2135.
3. S. J. Pike, M. D. Poli, W. Zawodny, J. Raftery, S. J. Webb, J. Clayden, *Org. Biomol. Chem.*, 2013, **11**, 3168.
4. N. Zheng, K. W. Anderson, X. Huang, H. N. Nguyen, S. L. Buchwald, *Angew. Chem. Int. Ed.*, 2007, **46**, 7509.
5. Z. Benli, Y. Qiliang, M. Dawei, *Angew. Chem. Int. Ed.*, 2007, **46**, 2598.
6. J. Alonso, N. Halland, M. Nazaré, O. R'Kyek, M. Urmann, A. Lindenschmidt, *Eur. J. Org. Chem.*, 2011, 234.
7. M. Akazome, T. Kondo, Y. Watanabe, *J. Org. Chem.*, 1993, **58**, 310.
8. Q. Shuai, G. Deng, Z. Chua, D. S. Bohle, C.-J. Li, *Adv. Synth. Catal.*, 2010, **352**, 632.
9. N. Takemura, Y. Kuninobu, M. Kanai, *Org. Lett.*, 2013, **15**, 844.















































































































































































































































































































































5a














8

